Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001193125-25-092133
Filing Date
2025-04-24
Accepted
2025-04-24 06:07:22
Documents
17
Period of Report
2025-06-17

Document Format Files

Seq Description Document Type Size
1 DEF 14A d940377ddef14a.htm   iXBRL DEF 14A 496170
3 GRAPHIC g940377dsp050a.jpg GRAPHIC 5343
4 GRAPHIC g940377dsp050b.jpg GRAPHIC 8275
5 GRAPHIC g940377g07y89.jpg GRAPHIC 40265
6 GRAPHIC g940377g19e45.jpg GRAPHIC 40265
7 GRAPHIC g940377g99n01.jpg GRAPHIC 33935
  Complete submission text file 0001193125-25-092133.txt   1085642

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rapp-20241231.xsd EX-101.SCH 2498
19 EXTRACTED XBRL INSTANCE DOCUMENT d940377ddef14a_htm.xml XML 1493
Mailing Address 1325 BOYLSTON STREET SUITE 401 BOSTON MA 02215
Business Address 1325 BOYLSTON STREET SUITE 401 BOSTON MA 02215 857-321-8020
Rapport Therapeutics, Inc. (Filer) CIK: 0002012593 (see all company filings)

EIN.: 880724208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-42121 | Film No.: 25863439
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)